Tokyo, May 22 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061635) titled 'Association of DNA methylation of inflammatory, anti-inflammatory, and longevity-related genes with complications and prognosis in patients with chronic kidney disease' on May 22.
Study Type:
Observational
Primary Sponsor:
Institute - Showa Medical University
Condition:
Condition - Chronic kidney disease
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - While chronic kidney disease(CKD)patients frequently develop cardiovascular and nutritional complications, the underlying pathophysiology remains unclarified. Recently, epigenetic modifications-specifically DNA methylation-have been implicated in various diseases. Since CKD-specific stressors, such as uremia, chronic inflammation, and oxidative stress, are closely associated with altered DNA methylation, epigenetic alterations in inflammatory and longevity-related genes likely drive disease progression and patient prognosis. This study aims to evaluate the relationship between targeted DNA methylation and complications in CKD patients(both non-dialysis and dialysis-dependent phases)compared to healthy controls.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
Gender - Male and Female
Key inclusion criteria - Hemodialysis Patients: Patients undergoing maintenance hemodialysis at Kawasaki Clinic, Ebara Clinic, Monnaka Kidney Clinic, Toyosu Kidney Clinic, Shibagaki Clinic Jiyugaoka, Shibagaki Clinic Togoshi, Shibagaki Clinic Kugahara, Nagahara Sanwa Clinic, and Yukigaya Sanwa Clinic.
CKD Patients: Patients undergoing treatment at the Department of Nephrology, Showa Medical University Hospital, and the Department of Nephrology, Showa Medical University Koto Toyosu Hospital.
Healthy Controls: Subjects recruited at the Showa Medical University Clinical Pharmacology Research Institute.
Key exclusion criteria - 1)Patients under 20 years of age
2)Patients unable to provide written informed consent
3)Patients with advanced cancer, active hepatitis, infectious diseases, or collagen diseases
Target Size - 250
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2013 Year 11 Month 08 Day
Date of IRB - 2013 Year 11 Month 08 Day
Anticipated trial start date - 2016 Year 05 Month 30 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070514
Disclaimer: Curated by HT Syndication.
